Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant

[News]

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

More... (http://www.news-medical.net/news/20100809/Aragon-initiates-dosing-in-ARN-509-Phase-12-clinical-trial-for-castration-resistant-prostate-cancer.aspx)